Clinical Trial Update: Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating IMM01 in combination with tislelizumab for advanced solid tumors and Classic Hodgkin lymphoma is ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classic Hodgkin Lymphoma
• Solid Tumor

Drugs mentioned

• IMM01 (IMM01)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Conditions: Solid Tumor, Classic Hodgkin Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN